Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $150.00

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) had its price target upped by investment analysts at Guggenheim from $148.00 to $150.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage presently has a "buy" rating on the biotechnology company's stock. Guggenheim's price target would indicate a potential upside of 26.89% from the stock's current price.

A number of other research analysts have also issued reports on the company. Needham & Company LLC reiterated a "buy" rating and set a $205.00 target price on shares of Sarepta Therapeutics in a research report on Thursday. Jefferies Financial Group began coverage on Sarepta Therapeutics in a research report on Monday, October 21st. They set a "buy" rating and a $165.00 target price on the stock. Barclays dropped their target price on Sarepta Therapeutics from $226.00 to $203.00 and set an "overweight" rating on the stock in a research report on Thursday, August 8th. Piper Sandler reduced their price target on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an "overweight" rating on the stock in a report on Thursday, August 8th. Finally, Raymond James reaffirmed an "outperform" rating and set a $150.00 price target on shares of Sarepta Therapeutics in a research note on Thursday, October 10th. One equities research analyst has rated the stock with a hold rating, twenty have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $181.33.

Sarepta Therapeutics Stock Performance

Shares of SRPT traded down $9.76 during trading hours on Thursday, hitting $118.21. The stock had a trading volume of 1,546,889 shares, compared to its average volume of 1,229,456. The stock has a fifty day moving average price of $126.54 and a 200 day moving average price of $132.85. Sarepta Therapeutics has a 12 month low of $75.85 and a 12 month high of $173.25. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. The firm has a market capitalization of $11.27 billion, a PE ratio of 264.54 and a beta of 0.81.

Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last released its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.06. The business had revenue of $362.90 million during the quarter, compared to the consensus estimate of $394.38 million. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The business's revenue for the quarter was up 38.9% compared to the same quarter last year. During the same period last year, the company earned ($0.27) earnings per share. Analysts anticipate that Sarepta Therapeutics will post 1.48 EPS for the current year.

Insider Buying and Selling at Sarepta Therapeutics

In related news, Director Michael Andrew Chambers bought 37,038 shares of the business's stock in a transaction that occurred on Friday, August 16th. The shares were bought at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the transaction, the director now directly owns 284,034 shares in the company, valued at approximately $38,003,749.20. This represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the transaction, the chief financial officer now owns 33,946 shares of the company's stock, valued at $4,662,822.56. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Michael Andrew Chambers purchased 37,038 shares of Sarepta Therapeutics stock in a transaction dated Friday, August 16th. The shares were purchased at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the transaction, the director now directly owns 284,034 shares in the company, valued at approximately $38,003,749.20. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 7.70% of the company's stock.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of large investors have recently added to or reduced their stakes in SRPT. Capital International Investors lifted its position in Sarepta Therapeutics by 1.6% in the first quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company's stock valued at $623,676,000 after purchasing an additional 76,032 shares during the last quarter. Farallon Capital Management LLC boosted its position in Sarepta Therapeutics by 102.8% during the 1st quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company's stock valued at $317,630,000 after buying an additional 1,243,427 shares during the period. Thrivent Financial for Lutherans grew its holdings in Sarepta Therapeutics by 6.3% in the 2nd quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company's stock worth $101,858,000 after acquiring an additional 37,940 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its position in shares of Sarepta Therapeutics by 26.3% in the first quarter. Jacobs Levy Equity Management Inc. now owns 579,637 shares of the biotechnology company's stock valued at $75,040,000 after acquiring an additional 120,535 shares during the period. Finally, abrdn plc raised its stake in shares of Sarepta Therapeutics by 30.7% during the third quarter. abrdn plc now owns 431,098 shares of the biotechnology company's stock valued at $53,935,000 after acquiring an additional 101,253 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company's stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.